Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosphenytoin - Bristol-Myers Squibb/Pfizer

Drug Profile

Fosphenytoin - Bristol-Myers Squibb/Pfizer

Alternative Names: ACC 9653; ACC 9653-010; Cerebyx; Cereneu; Fosphenytoin sodium; Fostoin; NPC-06; PD 135711-15B; Pro-Epanutin; Prodilantin; Prophenytoin

Latest Information Update: 09 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Nobelpharma; Pfizer
  • Class Analgesics; Antiepileptic drugs; Hydantoins; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy
  • Phase III Pain
  • Phase II Neuropathic pain
  • Discontinued Stroke

Most Recent Events

  • 23 Aug 2023 Nobelpharma completes a phase III trial in Pain in Japan (IV) (NCT05480553)
  • 30 Jun 2023 Nobelpharma in collaboration with Pfizer anticipates a regulatory approval for Neuropathic pain in September 2024 (Nobelpharma pipeline, August 2023)
  • 05 Aug 2022 Phase-III clinical trials in Pain in Japan (IV) (NCT05480553)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top